Vilya
Vilya, founded in 2022 in Seattle, USA, develops macrocyclic drugs using machine learning and artificial intelligence.
About
Vilya, founded in 2022 in Seattle, USA, develops macrocyclic drugs using machine learning and artificial intelligence. The company has 40 employees, approximately one quarter of whom are based in the Seattle area.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2024-06Series A$71M
Investors · ARCH Venture Partners, Lifeforce Capital, Altitude Life Science Ventures, Madrona Ventures, NVentures, Menlo VenturesSource · SVTR Weekly #056
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Vilya
Macrocycle drug development using machine learning and AI
Series A · $71M · 2024-06
$71M
United States
BusinessLatest roundTotal raisedDate- Odyssey Therapeutics
Small-molecule and protein therapeutics developed with AI and machine learning
Series C · $101M · 2023-12
$101M - Seismic Therapeutic
Uses machine learning to develop new drugs for autoimmune diseases
Undisclosed · $121M · 2023-12
$121M - PhaseV
Uses machine learning to help pharmaceutical companies design and analyze adaptive clinical trials
Series A · $65M · 2025-05
$65M
China
BusinessLatest roundTotal raisedDate- Drug Farm
Drug developer using genetics and AI to discover first-in-class targets
Series D+ · $55M · 2026-07
$55M - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials
Series D+ · $210M · 2025-03
$210M - Deep Pharma
AI-driven drug discovery and clinical development platform
Series D+ · $200M · 2026-03
$200M
Europe
BusinessLatest roundTotal raisedDate- Relation Therapeutics
Multi-omics plus active graph machine learning to discover and validate novel drug targets, partnered with GSK (fibrosis and osteoarthritis)
Undisclosed · $61M · 2025-12
$61M - Healx
AI to discover and develop treatments for rare diseases
Undisclosed · $47M · 2024-08
$47M - Aqemia
Cancer drug discovery using generative AI and quantum physics
Undisclosed · $71M · 2024-12
$71M
Other / unspecified
BusinessLatest roundTotal raisedDate- Altis Labs
AI imaging biomarker platform across solid tumor types and therapeutic areas
Series A · $31M · 2026-09
$31M - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - Congruence
Computation-driven drugs for genetic diseases (including CGX-926)
Undisclosed · $32M · 2025-09
$32M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
39 Life Sciences deals in the last 24 months · 25 at a nearby stage · 35 in Seattle Metro
Request intro →Y Combinator
38 Life Sciences deals in the last 24 months · 33 at a nearby stage · 31 in Seattle Metro
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 12 at a nearby stage · 22 in Seattle Metro
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 10 at a nearby stage · 20 in Seattle Metro
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 6 at a nearby stage · 15 in Seattle Metro
Request intro →Lightspeed
16 Life Sciences deals in the last 24 months · 11 at a nearby stage · 14 in Seattle Metro
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.